Naringenin suppresses colorectal Cancer progression by targeting the Gankyrin/PI3K /AKT/GSK-3β/β-catenin signaling Axis
Cytotechnology · 2026-06 · 78 (3)
DOI: 10.1007/s10616-026-00948-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytotechnology, online erschienen am 11.04.2026. Verfasst von Chengxing Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Jiangmen Central Hospital, Jiangmen, 529000 China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Guangdong Administration of Traditional Chinese Medicine Research Foundation, Technology Project of Traditional Chinese Medicine and Combined Chinese and Western Medicine, Jiangmen Planned Project of Science and Technology.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains one of the most prevalent and lethal malignancies worldwide. Natural products derived from Traditional Chinese Medicine (TCM), offer promising therapeutic potential due to their multitarget effects and low toxicity. Naringenin (NAR), a major flavonoid found in citrus peel (chenpi), has shown anticancer activity in several tumor types; however, its mechanism in CRC remains incompletely understood. We combined network pharmacology, molecular docking, and experimental validation to explore the anti-CRC mechanisms of NAR. Bioinformatics databases were used to identify overlapping targets between NAR and CRC. Enrichment analyses and protein-protein interaction (PPI) networks were performed. The interaction between NAR and core targets was confirmed via molecular docking. In vitro assays (CCK-8, colony formation, flow cytometry, Transwell) and Western blotting were used to assess the functional and molecular effects of NAR and Gankyrin modulation. In vivo efficacy and toxicity were evaluated using a CRC xenograft model in nude mice. Network pharmacology identified AKT1 as a hub target, and pathway enrichment highlighted PI3K-AKT signalling. Naringenin (NAR) dose-dependently suppressed colorectal cancer (CRC) cell proliferation, migration and invasion, while promoting apoptosis. In vivo, NAR significantly inhibited tumour growth without overt systemic toxicity. Mechanistically, NAR attenuated the Gankyrin-PI3K-AKT-GSK-3β-β-catenin axis. In gain-of-function rescue experiments, Gankyrin overexpression partially blunted the anti-proliferative and anti-invasive effects of NAR, supporting a Gankyrin-dependent component of NAR activity. This study reveals that NAR exerts anti-CRC effects by targeting the Gankyrin/ PI3K/AKT/GSK-3β/β-catenin pathway, supporting its potential as a safe and effective therapeutic agent in CRC treatment. Supplementary Information: The online version contains supplementary material available at 10.1007/s10616-026-00948-2.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Jiangmen Central Hospital, Jiangmen, 529000 China.
- Digestive Disease Research Center, Jiangmen Central Hospital, Jiangmen, 529000 China.
- School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529000 China.
- Guangdong Medical University, Zhanjiang, 524000 China.
- Department of General Surgery, Guangzhou First People's Hospital, Guangzhou, 510000 China.
Förderung
- Guangdong Administration of Traditional Chinese Medicine Research Foundation
- Technology Project of Traditional Chinese Medicine and Combined Chinese and Western Medicine
- Jiangmen Planned Project of Science and Technology
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Wang, C., Lin, W., Wu, C., Zhou, C., Gao, Y., Ma, Y., He, C., Wei, J., Li, L., Wu, R., Zhao, J., & He, Y. (2026). Naringenin suppresses colorectal Cancer progression by targeting the Gankyrin/PI3K /AKT/GSK-3β/β-catenin signaling Axis. Cytotechnology, 78(3). https://doi.org/10.1007/s10616-026-00948-2
Vancouver
Wang C, Lin W, Wu C, Zhou C, Gao Y, Ma Y, et al. Naringenin suppresses colorectal Cancer progression by targeting the Gankyrin/PI3K /AKT/GSK-3β/β-catenin signaling Axis. Cytotechnology. 2026;78(3). doi:10.1007/s10616-026-00948-2
BibTeX
@article{Wang2026,
author = {Wang, Chengxing and Lin, Weixing and Wu, Chunbo and Zhou, Chaorong and Gao, Yuan and Ma, Yongfeng and He, Canxiu and Wei, Jianchang and Li, Lianmei and Wu, Rihui and Zhao, Jinglin and He, Yaoming},
title = {Naringenin suppresses colorectal Cancer progression by targeting the Gankyrin/PI3K /AKT/GSK-3β/β-catenin signaling Axis},
journal = {Cytotechnology},
year = {2026},
volume = {78},
number = {3},
doi = {10.1007/s10616-026-00948-2}
}
EUVIMED